Structure–activity relationships of non-imidazole H3 receptor ligands. Part 1
摘要:
SAR studies for novel non-imidazole containing H-3 receptor antagonists with high potency and selectivity for rat H-3 receptors are described. A high throughput screening lead, A-923, was further elaborated in a systematic manner to clarify a pharmacophore for this class of aryloxyalkyl piperazine based compounds. (C) 2002 Elsevier Science Ltd. All rights reserved.
Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
申请人:——
公开号:US20030166644A1
公开(公告)日:2003-09-04
Use of compounds to inhibit hormone-sensitive lipase, pharmaceutical compositions comprising the compounds, methods of treatment employing these compounds and compositions, and novel compounds. The present compounds are inhibitors of hormone-sensitive lipase and may be useful in the treatment and/or prevention of medical disorders where a decreased activity of hormone-sensitive lipase is desirable.
A series of novel dithiocarbamate-chalcone derivates were designed, synthesized and evaluated for antiproliferative activity against three selected cancer cell lines (EC-109, SK-N-SH and MGC-803). Majority of the synthesized compounds exhibited moderate to potent activity against all the cancer cell lines assayed. Particularly, compounds II2 and II5 exhibited the excellent growth inhibition against
Use of compounds for decreasing activity of hormone-sensitive
申请人:——
公开号:US20030166690A1
公开(公告)日:2003-09-04
Use of compounds to inhibit hormone-sensitive lipase, pharmaceutical compositions comprising the compounds, methods of treatment employing these compounds and compositions, and novel compounds. The present compounds are inhibitors of hormone-sensitive lipase and may be useful in the treatment and/or prevention of medical disorders where a decreased activity of hormone-sensitive lipase is desirable.
Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
申请人:Wong C.W. Norman
公开号:US20060205792A1
公开(公告)日:2006-09-14
The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.
Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases
申请人:Wong Norman C.W.
公开号:US20110082176A1
公开(公告)日:2011-04-07
The present disclosure provides non-naturally occurring polyphenol compounds that upregulate the expression of Apolipoprotein A-I (ApoA-I). The disclosed compositions and methods can be used for treatment and prevention of cardiovascular disease and related disease states, including cholesterol or lipid related disorders, such as, e.g., atherosclerosis.